What it's for (Indications)
- Glipizide and metformin combination therapy is primarily indicated as an adjunct to diet and exercise for the management of type 2 diabetes mellitus in adult patients.
- This medication is specifically prescribed when diet and exercise alone do not achieve adequate glycemic control, or when monotherapy with either glipizide or metformin is insufficient to attain desired glycemic targets.
- It is also suitable for patients whose blood glucose levels are not adequately controlled on a regimen of glipizide and metformin as individual components administered concomitantly.
- The therapeutic goal of this combination is to improve overall glycemic parameters, including fasting plasma glucose (FPG), postprandial glucose (PPG), and glycosylated hemoglobin (HbA1c) levels.
- This dual-acting formulation addresses the multifaceted pathophysiology of type 2 diabetes by leveraging glipizide's ability to stimulate insulin secretion from pancreatic beta cells and metformin's mechanisms of reducing hepatic glucose production, decreasing intestinal glucose absorption, and enhancing peripheral insulin sensitivity.
- It is crucial to emphasize that this medication is not indicated for the treatment of type 1 diabetes mellitus or for diabetic ketoacidosis, as its mechanism of action relies on the presence of functional pancreatic beta cells.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage must be individualized based on effectiveness and tolerance, not exceeding a maximum daily dose of 20 mg glipizide/2000 mg metformin. It should be given with meals, initiated at a low dose, with gradual dose escalation. This approach helps to avoid hypoglycemia, reduce gastrointestinal side effects, and determine the minimum effective dose. Blood glucose monitoring should be used during initial treatment and dose titration, and HbA1c should be measured at intervals of approximately 3 months. |
Safety & Warnings
Common Side Effects
- Common side effects include hypoglycemia, stomach upset (which may present as diarrhea), upper respiratory infection, and dizziness.
- Other gastrointestinal side effects may also occur.
Serious Warnings
- Black Box Warning: Lactic Acidosis: Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset is often subtle, accompanied by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis is characterized by elevated blood lactate levels (> 5 mmol/Liter) and anion gap acidosis (without evidence of ketonuria).
- Avoid use during pregnancy and lactation.
- Patients should avoid driving or operating machinery if their ability is affected by the medication.
- Alcohol consumption should be avoided while taking this medicine.
- Consult a doctor as a precaution before taking this medicine if you have mild to moderate renal or hepatic impairment.
- Dosage must be individualized and initiated at a low dose with gradual escalation to avoid hypoglycemia (due to glipizide) and reduce gastrointestinal side effects (due to metformin).
- Appropriate blood glucose monitoring is essential.
How it Works (Mechanism of Action)
Glipizide and metformin hydrochloride tablets combine glipizide and metformin hydrochloride, two antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control. Glipizide lowers blood glucose by stimulating insulin release from the pancreas, dependent upon functioning beta cells. Metformin hydrochloride is an antihyperglycemic agent.
Commercial Brands (Alternatives)
No other brands found for this formula.